Basic HTML Version
83
Marcin Barylski,
Skuteczność amlodipiny w terapii nadciśnienia
www.chsin.viamedica.pl
sion Study. Final results. Treatment of Mild Hypertension Study Research
Group.
JAMA
1993; 270: 713–724.
11. Waeber B., Burnier M., Brunner H.R. Compliance with antihypertensive
therapy.
Clin. Exp. Hypertens.
1999; 21: 973–985.
12. Heber M.E, Brigden G., Al-Khawaja I., Raftery E.B. 24 h blood pressure
control with the once daily calcium antagonist, amlodipine.
Br. J. Clin. Phar-
macol.
1989; 27: 359–365.
13. Burris J.F., Allenby K.S., Mroczek W.J. The effect of amlodipine on ambu-
latory blood pressure in hypertensive patients.
Am. J. Cardiol.
1994; 73:
39A–43A.
14. Levine C.B., Fahrbach K.R., Frame D. i wsp. Effect of amlodipine on systolic
blood pressure.
Clin. Ther.
2003; 25: 35–57.
15. Calvo C., Gude F., Abellan J. i wsp. A comparative evaluation of amlodipine
and hydrochlorothiazide as monotherapy in the treatment of isolated systolic
hypertension in the elderly.
Clin. Drug Invest.
2000; 19: 317–326.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial. Major outcomes in high-risk hypertensive patients randomized
to angiotensin-converting enzyme inhibitor or calcium channel blocker vs
diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT).
JAMA
2002; 288: 2981–2997.
17. Chobanian A.V., Bakris G.L., Black H.R. i wsp.; Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
National Heart, Lung, and Blood Institute; National High Blood Pressure
Education Program Coordinating Committee. Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure.
Hypertension
2003; 42: 1206–1252.
18. Dahlöf B., Sever P.S., Poulter N.R. i wsp.; ASCOT Investigators. Prevention
of cardiovascular events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding bendroflumethiazide
as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pres-
sure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled
trial.
Lancet
2005; 366: 895–906.
19. Williams B., Lacy P.S., Thom S.M. i wsp.; CAFE Investigators; Anglo-Scan-
dinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee
and Writing Committee. Differential impact of blood pressure-lowering
drugs on central aortic pressure and clinical outcomes: principal results
of the Conduit Artery Function Evaluation (CAFE) study.
Circulation
2006;
113: 1213–1225.
20. Julius S., Kjeldsen S.E., Weber M. i wsp.; VALUE trial group: Outcomes
in hypertensive patients at high cardiovascular risk treated with regimens
based on valsartan or amlodipine: the VALUE randomised trial.
Lancet
2004; 363: 2022–2031.
21. Jamerson K., Weber M.A., Bakris G.L. i wsp. for the ACCOMPLISH Trial
Investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hy-
pertension in High-Risk Patients.
N. Engl. J. Med.
2008; 359: 2417–2428.
22. Zasady postępowania w nadciśnieniu tętniczym— 2011 rok.
Nadciśnienie
Tętnicze
2011; 15: 55–82.
23. Deanfield J.E., Detry J.M., Lichtlen P.R. i wsp. Amlodipine reduces transient
myocardial ischemia in patients with coronary artery disease: double-blind
Circadian Anti-Ischemia Program in Europe (CAPE Trial).
J. Am. Coll. Cardiol.
1994; 24: 1460–1467.
24. Nissen S.E., Tuzcu E.M., Libby P. i wsp. Effect of antihypertensive agents
on cardiovascular events in patients with coronary disease and normal
blood pressure: the CAMELOT study: a randomized controlled trial.
JAMA
2004; 292: 2217–2225.
25. Messerli F.H., Bakris G.L., Ferrera D. Efficacy and safety of coadministered
amlodipine and atorvastatin in patients with hypertension and dyslipidemia:
results of the AVALON trial.
J. Clin. Hypertens.
2006; 8: 571–581.
26. Blank R., LaSalle J., Reeves R. i wsp. Single-pill therapy in the treatment of
concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin
gemini study).
J. Clin. Hypertens
. 2005; 7: 264–273.
27. Grabowski M., Tykarski A., Kostka-Jeziorny K. Leczenie nadciśnienia tętni-
czego u pacjentów z przewlekłymi chorobami układu oddechowego.
Forum
Medycyny Rodzinnej
2007; 1: 95–108.
28. Kivity S., Brayer M., Topilsky M. Combined effect of nifedipine and diltiazem
on methacholine-induced bronchoconstriction in asthmatic patients.
Ann.
Allergy
1992; 68: 175–179.
29. Lv Y., Zou Z., Chen G.M. i wsp. Amlodipine and angiotensin-converting
enzyme inhibitor combination versus amlodipine monotherapy in hyperten-
sion: a meta-analysis of randomized controlled trias.
Blood Press. Monit.
2010; 15: 195–204.
30. Ioulios P., Charalampos M., Efrossini T. The spectrum of cutaneous reac-
tions associated with calcium antagonists: A review of the literature and
the possible etiopathogenic mechanisms.
Dermatol. Online J.
2003; 9: 6.
31. Messeri F.H. Vasodilatatory edema: a common side effect of antihyperten-
sive therapy.
Curr. Cardiol. Rep
. 2002; 4: 479–482.
32. Bieńkowski P. Lek oryginalny a lek generyczny: ten sam czy inny lek?
Terapia
2010; 4: 63–66.
33. EMEA/CHMP/EWP/40326/2006: Questions & Answers on the Bioavailability
and Bioequivalence Guideline, EMEA 2006.
34. Janicki S., Sznitowska M., Zieliński W. Dostępność farmaceutyczna i do-
stępność biologiczna leków. Ośrodek Informacji Naukowej „Polfa” sp. z o.o.,
Warszawa 2001.
35. Spławiński J. O biorównoważności w Berlinie.
Pigułka
2008; 22: 3–6.
36. Majkowski J., Lasoń W., Daniel W. i wsp. Leki oryginalne i generyczne
w leczeniu padaczki — problemy biofarmaceutyczne, farmakokinetyczne,
farmakologiczne, kliniczne i ekonomiczne.
Epileptologia
2004; 12: 365–389.
37. Reiffel J.A. Issues in the use of generic antiarrhythmic drugs.
Curr. Opin.
Cardiol.
2001; 16: 23–29.
38. Woroń J., Kostka-Trąbka E. Leki oryginalne czy generyczne w farmakoterapii
kardiologicznej? Jak dokonać racjonalnego wyboru?
Terapia
2010; 1: 79–81.